tbuckley/cabot-search huggingface dataset:
5-Year Outcomes After Transcatheter or Surgical Aortic Valve Replacement in Low-Risk Patients With Aortic Stenosis
Authors: John K Forrest, Steven J Yakubov, G Michael Deeb, Hemal Gada, Mubashir A Mumtaz, Basel Ramlawi, Tanvir Bajwa, John Crouch, William Merhi, Stephane Leung Wai Sang, Neal S Kleiman, George Petrossian, Newell B Robinson, Paul Sorajja, Ayman Iskander, Pierre Berthoumieu, Didier Tchétché, Christopher Feindel, Eric M Horlick, Shigeru Saito, Jae K Oh, Yoojin Jung, Michael J Reardon
Journal: Journal of the American College of Cardiology (2025)

The Evolut Low Risk trial demonstrated that transcatheter aortic valve replacement (TAVR) was noninferior to surgery for the primary endpoint of all-cause mortality or disabling stroke at 2 years. Outcomes at 5 years have not been reported. This study sought to evaluate 5-year clinical and hemodynamic outcomes with TAVR vs surgery in patients from the Evolut Low Risk trial. We randomly assigned low-risk patients with severe aortic stenosis to TAVR or surgery. The primary endpoint was a composite of all-cause mortality or disabling stroke. Secondary endpoints included clinical, echocardiographic, and quality-of-life outcomes through 5 years. A total of 1,414 patients underwent an attempted implant (n = 730 TAVR, n = 684 surgery). The mean age was 74 years (range 51-88 years), and women accounted for 35% of patients. At 5 years the Kaplan-Meier estimate for the primary endpoint of all-cause mortality or disabling stroke was 15.5% for the TAVR group and 16.4% for the surgery group (P = 0.47). The Kaplan-Meier estimates in the TAVR and surgery groups for all-cause mortality were 13.5% and 14.9% (P = 0.39) and for disabling stroke were 3.6% and 4.0% (P = 0.57). Cardiovascular mortality was 7.2% in the TAVR group and 9.3% in the surgery group (P = 0.15). Noncardiovascular mortality in the TAVR group was 6.8% and 6.2% in the surgery group (P = 0.73). A site-level vital status sweep was performed for patients who were lost to follow-up or withdrew from the study. With the addition of these patients, the all-cause mortality rate at 5 years for patients undergoing TAVR was 14.7% and for surgery was 15.2% (P = 0.74). Over 5 years, valve reintervention rate was 3.3% for TAVR and 2.5% for surgery (P = 0.44). A sustained improvement in quality of life was observed in both treatment arms with mean Kansas City Cardiomyopathy Questionnaire summary score of 88.3 ± 15.8 in TAVR and 88.5 ± 15.8 in surgery. At 5 years, patients with severe aortic stenosis who were treated with either TAVR or surgery had comparable rates of all-cause mortality or disabling stroke. Valve durability and performance were excellent in both arms. This midterm evaluation reinforces the position of TAVR as noninferior to surgery in patients with severe aortic stenosis at low surgical risk (Medtronic Evolut Transcatheter Aortic Valve Replacement in Low Risk Patients; NCT02701283).
Real-world telemonitoring and remote support for home non-invasive ventilation to improve therapy effectiveness: the exploratory, multicentre randomised eVENT study
Authors: Arnaud Prigent, Joëlle B Texereau, Claude Schmitz, Cécile Ropars, Jean-Marc Degreef, Marion Teulier, Christian Darne, Franck Lavergne, Hélène Pasche, Capucine Morelot-Panzini
Journal: Thorax (2025)

Rationale Telemonitoring has shown benefits during the initiation of home non-invasive ventilation (NIV) but evidence is lacking regarding its use during follow-up. A French national telemonitoring programme incorporating remote support and therapeutic education is designed to improve patient pathways and reduce healthcare resource utilisation. This study investigated the impact of the telemonitoring programme versus usual follow-up on the effectiveness of home NIV. Methods The prospective, multicentre, open-label eVENT trial enrolled adults recently started on home NIV. Participants were randomised to the telemonitoring or usual follow-up group. In the telemonitoring group, a CE-marked algorithm generated alerts based on teletransmitted ventilator data. Specialised nurses managed alerts and provided therapeutic education. The primary outcome was mean nocturnal transcutaneous carbon dioxide level (PtCO 2 ) on NIV after 6 months. Results 56 patients were randomised and 53 were analysed (telemonitoring: n=27, usual follow-up: n=26). At 6 months, mean PtCO 2 did not differ significantly between the telemonitoring and usual follow-up groups (42.1±6.1 vs 43.9±6.4 mm Hg; p=0.352) but mean room air partial arterial carbon dioxide pressure (PaCO 2 ) was significantly lower in the telemonitoring versus usual follow-up group (41.7±6.8 vs 46.2±3.5 mm Hg; p=0.003). The proportion of participants without diurnal or nocturnal hypercapnia at 6 months was 82.6% with telemonitoring and 27.3% with usual follow-up (p&lt;0.001). Compared with usual follow-up, the telemonitoring group had greater NIV use, more days with NIV usage ≥4 hour and less non-intentional leaks. Conclusions In patients on home NIV, PtCO 2 was similar with telemonitoring and usual follow-up, but PaCO 2 levels and the quality of ventilatory support were significantly better with telemonitoring. Trial registration number NCT04615078 .
A consensus of European experts on the definition of ventilator-associated pneumonia recurrences obtained by the Delphi method: the RECUVAP study
Authors: Antoine Gaillet, Charles-Edouard Luyt, Jean-Francois Timsit, Karim Asehnoune, Francois Barbier, Matteo Bassetti, Lila Bouadma, Adrien Bouglé, Jean Chastre, Andrew Conway Morris, Jan J De Waele, François Dépret, George Dimopoulos, Stephan Ehrmann, Santiago Ewig, Muriel Fartoukh, Arnaud Foucrier, José Garnacho-Montero, Sami Hraiech, Marc Leone, Demosthenes Makris, Ignacio Martin-Loeches, Dimitrios Matthaiou, Antoine Monsel, Philippe Montravers, Saad Nseir, José-Artur Paiva, Laurent Papazian, Garyfallia Poulakou, Pedro Póvoa, Jérôme Pugin, Alejandro H Rodriguez, Antoine Roquilly, Damien Roux, Anahita Rouzé, Fabio Silvio Taccone, Antoni Torres, Jean-Ralph Zahar, Emmanuel Weiss, Keyvan Razazi
Journal: Intensive Care Medicine (2025)
Angiography-derived fractional flow reserve versus intravascular ultrasound to guide percutaneous coronary intervention in patients with coronary artery disease (FLAVOUR II): a multicentre, randomised, non-inferiority trial
Authors: Xinyang Hu, Jinlong Zhang, Seokhun Yang, Jun Jiang, Xiaoping Peng, Dongsheng Lu, Yibin Pan, Lijun Guo, Jilin Li, Wenming He, Hao Zhou, Jun Pu, Jinyu Huang, Fan Jiang, Qiang Liu, Daqing Song, Liang Lu, Zhenfeng Cheng, Bin Yang, Jianliang Ma, Peng Chen, Shiqiang Li, Zhaohui Meng, Lijiang Tang, Yongzhen Fan, Eun-Seok Shin, Shenxian Tu, Chang-Wook Nam, William F Fearon, Bon-Kwon Koo, Jian'an Wang
Journal: The Lancet (2025)
Metabolic septic shock sub-phenotypes, stability over time and association with clinical outcome
Authors: David B Antcliffe, Elsa Harte, Humma Hussain, Beatriz Jiménez, Charlotte Browning, Anthony C Gordon
Journal: Intensive Care Medicine (2025)

Machine learning has shown promise to detect useful subgroups of patients with sepsis from gene expression and protein data. This approach has rarely been deployed in metabolomic datasets. Metabolomic data are of interest as they capture effects from the genome, proteome, and environmental. We aimed to discover metabolic sub-phenotypes of septic shock, examine their temporal stability and association with clinical outcome. Analysis was performed in two double-blind randomized trials in septic shock (LeoPARDS (1402 samples from 470 patients) and VANISH (493 samples from 173 patients)). Patients were included soon after the onset of shock and had serum collected at up to four time points. Metabolic clusters were identified from 474 metabolites using k-means clustering in LeoPARDS and predicted in VANISH with an elastic net classifier. Three sub-phenotypes were found. The main determinants of cluster membership were lipid species, especially lysophospholipids. Low lysophospholipid sub-phenotypes were associated with higher circulating cytokine levels. Persistence of low lysophospholipid sub-phenotypes was associated with higher mortality compared to the high lysophospholipid sub-phenotype (LeoPARDS: cluster 2 odds ratio 3.66 (95% CI 1.88-7.20), p = 0.0001, cluster 3 2.49 (1.29-4.81), p = 0.006; VANISH: cluster 2 4.13 (1.17-15.61), p = 0.03), cluster 3 3.22 (1.09-9.92), p = 0.04, vs cluster 1). We found no heterogeneity of treatment effect for any of the trial interventions by baseline metabolic sub-phenotype. Three metabolic subgroups exist in septic shock which evolve over time. Persistence of low lysophospholipid sub-phenotypes is associated with mortality. Monitoring these subgroups could help identify patients at risk of poor outcome and direct novel therapies such as lysophospholipid supplementation. Clinicaltirals.gov Identifiers, VANISH: ISRCTN 20769191, LeoPARDS: ISRCTN12776039.
WHO Classification of Tumours: evolution of a global resource in the molecular era
Authors: Jennelle C Hodge, George J Netto, Bharat Rekhi, Wendy A Cooper, Michael Eden, Andrew S Field, Vicky Goh, James G Kench, Joseph D Khoury, Katia R M Leite, Zhiyong Liang, Daichi Maeda, Miguel Reyes-Múgica, Brian Rous, Aleš Ryška, Shahin Sayed, Antonia Sepulveda, Chanjuan Shi, Gary Tse, Peter Schirmacher, Dilani Lokuhetty
Journal: The Lancet Oncology (2025)
European Society of Intensive Care Medicine (ESICM) 2025 clinical practice guideline on fluid therapy in adult critically ill patients: part 2—the volume of resuscitation fluids
Authors: Armand Mekontso Dessap, Fayez AlShamsi, Alessandro Belletti, Daniel De Backer, Anthony Delaney, Morten Hylander Møller, Segolène Gendreau, Glenn Hernandez, Flavia R Machado, Mervyn Mer, Manuel Ignacio Monge Garcia, Sheila Nainan Myatra, Zhiyong Peng, Anders Perner, Michael R Pinsky, Sameer Sharif, Jean-Louis Teboul, Antoine Vieillard-Baron, Waleed Alhazzani
Journal: Intensive Care Medicine (2025)
Outcomes after fractional flow reserve-guided percutaneous coronary intervention versus coronary artery bypass grafting (FAME 3): 5-year follow-up of a multicentre, open-label, randomised trial
Authors: William F Fearon, Frederik M Zimmermann, Victoria Y Ding, Kuniaki Takahashi, Zsolt Piroth, Albert H M van Straten, Laszlo Szekely, Giedrius Davidavičius, Gintaras Kalinauskas, Samer Mansour, Rajesh Kharbanda, Nikolaos Östlund-Papadogeorgos, Adel Aminian, Keith G Oldroyd, Nawwar Al-Attar, Nikola Jagic, Jan-Henk E Dambrink, Petr Kala, Oskar Angerås, Philip MacCarthy, Olaf Wendler, Filip Casselman, Nils Witt, Kreton Mavromatis, Steven E S Miner, Jaydeep Sarma, Thomas Engstrøm, Evald H Christiansen, Pim A L Tonino, Michael J Reardon, Hisao Otsuki, Yuhei Kobayashi, Mark A Hlatky, Kenneth W Mahaffey, Manisha Desai, Y Joseph Woo, Alan C Yeung, Nico H J Pijls, Bernard De Bruyne
Journal: The Lancet (2025)
Efficacy and safety of clopidogrel versus aspirin monotherapy in patients at high risk of subsequent cardiovascular event after percutaneous coronary intervention (SMART-CHOICE 3): a randomised, open-label, multicentre trial
Authors: Ki Hong Choi, Yong Hwan Park, Jong-Young Lee, Jin-Ok Jeong, Chan Joon Kim, Kyeong Ho Yun, Han Cheol Lee, Kiyuk Chang, Mahn-Won Park, Jang-Whan Bae, Joon-Hyung Doh, Byung Ryul Cho, Hee-Yeol Kim, Weon Kim, Ung Kim, Seung-Woon Rha, Young Joon Hong, Hyun-Jong Lee, Sung Gyun Ahn, Doo-Il Kim, Jang Hyun Cho, Sung Ho Her, Doo Soo Jeon, Seung Hwan Han, Jin-Bae Lee, Cheol Whan Lee, Danbee Kang, Joo Myung Lee, Taek Kyu Park, Jeong Hoon Yang, Soo-Youn Lee, Seung-Hyuk Choi, Hyeon-Cheol Gwon, Young Bin Song, Joo-Yong Hahn
Journal: The Lancet (2025)
Early Intra-Aortic Balloon Support for Heart Failure-Related Cardiogenic Shock
Authors: Nuccia Morici, Alice Sacco, Simone Frea, Matteo Rota, Luca Villanova, Carol Gravinese, Carlotta Sorini Dini, Nicoletta D'Ettore, Giulia Maj, Giulia D'Elio, Luciano Potena, Serafina Valente, Mario Sabatino, Giovanna Viola, Laura Garatti, Giovanni Amedeo Tavecchia, Letizia Bertoldi, Fabrizio Oliva, Navin K Kapur, Guido Tavazzi, Gaetano Maria De Ferrari, Federico Pappalardo
Journal: Journal of the American College of Cardiology (2025)
Survival Outcomes After Sudden Cardiac Arrest in Young Competitive Athletes From the United States
Authors: Bradley J Petek, Timothy W Churchill, Nathaniel Moulson, Randi Delong, Mary Catherine Minnig, Stephanie A Kliethermes, Aaron L Baggish, Joseph J Maleszewski, Kristen L Kucera, Kimberly G Harmon, Jonathan A Drezner
Journal: Journal of the American College of Cardiology (2025)
TNFAIP8L2 maintains Hair cell function and Regulates Age-related hearing loss via mTORC1 Signaling
Authors: Wen Li, Yu Li, Min Wang, Hao Liu, Guodong Hong, Luhan Jiang, Ziyi Liu, Yunhao Wu, Liangjie Yuan, Xiaoxu Zhao, Zuhong He, Siwei Guo, Yu Xiao, Xiuli Bi, Ming Xia, Guichang Zou, Lining Zhang, Jiangang Gao, Xiaolong Fu
Journal: Molecular Therapy (2025)
Targeting PD-1 and CD85j can restore intratumoral CD4<sup>+</sup>GzmB<sup>+</sup>T-cell functions to combat MHC-II-expressing tumors
Authors: Boyu Wang, Xu Wang, Tianlai Wang, Kelin Meng, Taiyan Yu, Yu Xi, Shaojie Hu, Hui Xiong, Rirong Qu, Zhiwei Yuan, Xue Wang, Chenxi Zeng, Wenbin Zou, Yitao Tian, Yixin Cai, Shengling Fu, Xiangning Fu, Lequn Li
Journal: Journal for ImmunoTherapy of Cancer (2025)

Background A subset of CD4 + T cells with cytotoxic activity has been identified, and these cells exert their effects by expressing perforin and granzymes. Despite the progress made in characterizing cytotoxic CD4 + T cells in various diseases, the status of cytotoxic CD4 + T cells in non-small cell lung cancer (NSCLC) and the underlying mechanisms involved in promoting intratumoral cytotoxic CD4 + T-cell activation remain unclear. Methods We used flow cytometry to examine the phenotypic and functional properties of CD4 + GzmB + T cells in the peripheral blood and tumor tissues of patients with NSCLC. Loss-of-function analyses and RNA sequencing were used to identify the underlying mechanisms involved in the effects of interleukin (IL)-15 on the restoration of CD4 + GzmB + T-cell function in vitro. A patient-derived lung cancer explant model and an animal model were used to verify the effects of immune checkpoint inhibitors on CD4 + GzmB + T-cell activation. Results In patients with NSCLC, impaired cytolytic function of tumor-infiltrated granzyme B (GzmB)-expressing CD4 + T cells was restored by IL-15 through activation of the AKT-FOXO1-T-bet axis. Moreover, IL-15 stimulation increased solute carrier family 7 member 5 (SLC7A5) expression in CD4 + GzmB + T cells in an Protein Kinase B (AKT)-dependent manner, and inhibition of SLC7A5 abrogated the effect of IL-15 on CD4 + GzmB + T cells. Additionally, we showed that the immune checkpoint molecules programmed cell death-1 (PD-1) and CD85j were mutually exclusively expressed in CD4 + GzmB + T cells and that dual targeting of PD-1 and CD85j enhanced the effector function of CD4 + GzmB + T cells by activating the AKT pathway. Notably, tumor cells expressing major histocompatibility complex (MHC)-II and IL-15 determine the effectiveness of CD4 + GzmB + T-cell-mediated antitumor immunity in response to immunotherapy. Conclusions Our study demonstrated that tumor-infiltrating CD4 + GzmB + T cells fail to eliminate tumors. Dual blockade of PD-1 and CD85j alongside IL-15 restores the effector function of CD4 + GzmB + T cells and drives CD4 + GzmB + T-cell transformation in the tumor microenvironment to combat MHC-II-expressing tumors.
IL-12-producing cytokine factories induce precursor exhausted T cells and elimination of primary and metastatic tumors
Authors: Amanda Nash, Jonathon DeBonis, Danna Murungi, Bertha Castillo, Boram Kim, Fangheng Hu, Courtney Chambers, Annie Nguyen, Andrea Hernandez, Zeshi Wang, Peter D Rios, Sofia Ghani, Ira Joshi, Douglas Isa, Ningbo Zheng, Weiyi Peng, Oleg A Igoshin, Jose Oberholzer, H Courtney Hodges, Nathan Reticker-Flynn, Omid Veiseh
Journal: Journal for ImmunoTherapy of Cancer (2025)

Background Curative responses to immunotherapy require the generation of robust systemic immunity with limited toxicity. Recruitment of T cell populations such as precursor exhausted T cells (Tpex) from lymphoid tissues to tumors is a hallmark of effective treatment. However, the ability to efficiently induce this recruitment is lacking in current immunotherapy approaches. Furthermore, systemic administration of immunotherapies frequently results in dose-limiting toxicities, yielding an inadequate therapeutic window for eliciting durable responses. Methods In this investigation, we evaluated the safety and antitumor efficacy of locally administered interleukin 12 (IL-12) using a clinically translatable cytokine delivery platform ( NCT05538624 ) to identify Tpex recruitment capabilities at tolerable cytokine doses. Results We show IL-12 cytokine factories can effectively treat a broad spectrum of cancer types. Single-cell RNA sequencing data suggests that the antitumor efficacy seen in our studies was due to retinal pigmented epithelial cells-mIL12 treatment inducing differentiation of Tpex cells within the tumor microenvironment. When administered in combination with checkpoint therapy, IL-12 cytokine factory treatment generated systemic abscopal immunity, preventing subcutaneous tumor outgrowth in 8/9 mice with colorectal cancer and lung metastasis in mice with melanoma. Furthermore, this platform was well tolerated in a non-human primate without signs of toxicity. Conclusions Our new immunotherapy approach provides a robust strategy for inducing Tpex recruitment and systemic immunity against a range of solid peritoneal malignancies, many incurable with current immunotherapy strategies. Notably, these features were achieved using IL-12, and by leveraging our technology, we avoided the toxicities that have prevented the translation of IL-12 to the clinic. Our findings provide a strong rationale for the clinical development of IL-12 cytokine factories.
Advancing gender equity in sport: a scoping review of international sport federation policies for pregnant, postpartum and parenting elite athletes
Authors: Margie H Davenport, Gyanjot Bains, Melanie Hayman, Chenxi Cai, Nonhlanhla S Mkumbuzi, Tara-Leigh McHugh
Journal: British Journal of Sports Medicine (2025)

Objective The aim was to synthesise international-level sport policies for pregnant, postpartum or parenting high-performance athletes in order to understand what policies currently exist and to identify policy gaps to be addressed. Design Scoping review. Data sources Online databases (MEDLINE, EMBASE, CINAHL, SPORTDiscuss, Evidence-Based Medicine Reviews (Ovid), Scopus, Web of Science and ClinicalTrials.gov) and Google up to 14 June 2024. Additionally, a targeted search of existing policies was conducted via the websites of International Federations (IFs) and continental sporting organisations (CSOs) in September 2023. Eligibility criteria We included policies from IFs recognised by the International Olympic Committee, and CSOs associated with the IFs that specifically address pregnant, postpartum or parenting athletes. Policies were a written principle of action adopted by the IFs/CSOs that provided any form of support during pregnancy, post partum or for parents. Results A total of 219 organisations (49 IFs; 170 CSOs) were identified and contacted, with 47/49 (96%) IFs and 15/170 (9%) CSOs responding. Sport policies related to pregnancy, postpartum or parenting athletes were identified from 20 IFs including (1) guidance on training/competition during and following pregnancy; (2) eligibility affected or training not advised; (3) protection from dismissal; (4) special rank, points or quota protection; (5) protections apply to adoption, surrogacy, miscarriage, stillbirth, egg freezing and/or fertility treatment; (6) duration of leave and if leave is paid and (7) breastfeeding support/space. No policies identified specific provisions for childcare support/space. Conclusions Less than half of all IFs have developed sport policies to support pregnant, postpartum and parenting athletes. Of the policies that do exist, most are limited in the extent to which they address the broad range of biopsychosocial supports that are necessary for facilitating optimal performance, enhancing long-term athlete health and addressing gender inequities that are deeply entrenched across all levels of sport. This review provides a critical piece of evidence needed to inform future policy development.
Targeted release of a bispecific fusion protein SIRPα/Siglec-10 by oncolytic adenovirus reinvigorates tumor-associated macrophages to improve therapeutic outcomes in solid tumors
Authors: Yenan Zhang, Bohao He, Peng Zou, Mengdi Wu, Min Wei, Chuning Xu, Jie Dong, Jiwu Wei
Journal: Journal for ImmunoTherapy of Cancer (2025)

Background The pleiotropic roles of tumor-associated macrophages (TAMs) render them attractive targets in antitumor drug development. CD47/SIRPα (signal regulatory protein alpha) and CD24/Siglec-10 (sialic acid-binding immunoglobulin-like lectin 10) signaling pathways have been found to suppress macrophage phagocytosis of malignant cells. Systemic blockade of CD47/SIRPα has shown severe side effects. Intratumoral delivery of a CD47 inhibitor by oncolytic viruses (OVs) may circumvent this hurdle. Methods To identify the characteristics of recombinant adenovirus (AdV)-SIRPα/Siglec-10, we conducted CCK8 assay, quantitative PCR, western blot, competitive binding assay, in vitro cytotoxicity assay, ELISA and phagocytosis assay. We investigated the antitumor immune responses of AdV-SIRPα/Siglec-10 using flow cytometry, various tumor-bearing mouse models, humanized tumor-bearing mouse models, immune cell depletion, RNA sequencing, and in vitro T cell activation assay. Results Here, we developed a novel AdV encoding a fusion protein composed of the extracellular domains of murine or human SIRPα and Siglec-10 (SIRPα/Siglec-10), termed AdV-mSS or AdV-huSS. The SIRPα/Siglec-10 was effectively secreted by cells infected with AdV-mSS and functioned as a dual blocker of CD47 and CD24, thereby significantly enhancing macrophage phagocytosis. In a series of tumor models, including subcutaneous and ascitic H22 hepatocellular carcinoma (HCC), subcutaneous Hepa1-6 HCC, MC38 colorectal carcinoma, and Lewis lung carcinoma, AdV-mSS treatment markedly enhanced antitumor efficacy. Mechanistically, AdV-mSS reprogrammed TAMs toward an antitumor phenotype and enhanced the expression of major histocompatibility complex (MHC)-I/II, promoting CD8+T cell proliferation and activation. Depletion of either macrophages or CD8+T cells abrogated the antitumor efficacy of AdV-mSS. Similarly, in a humanized LM3 HCC mouse model, AdV-huSS significantly inhibited tumor growth and prolonged survival. Conclusions Dual SIRPα/Siglec-10 inhibitor delivered intratumorally by AdV not only reinvigorated the TAM-CD8+T cell axis but also potentially reduced the risk of off-target effects. Further investigation of AdV-huSS in patients with cancer is warranted in the near future.
First reported case of a spontaneous and healthy pregnancy in a woman with persistent CAR T-cells 5 years after treatment for diffuse large B-cell lymphoma
Authors: Ethan Abraham Canty, Lori Broderick, Daniel Flaherty, Marin Xavier, Sunita D Nasta, Lina Dajani, Andrew A White
Journal: Journal for ImmunoTherapy of Cancer (2025)

Chimeric antigen receptor T-cell (CAR T-cell) therapy has significantly advanced cancer treatments and remission rates; however, questions exist regarding the impacts on both fertility and immune effects on infants born to mothers who have undergone CAR T-cell therapy. There are no known reported cases of persistence of CAR T-cells after cancer therapy in pregnancy. Here, we present a case of a woman with relapsed refractory diffuse large B-cell lymphoma who undertook an experimental CAR T-cell therapy, had persistence of CAR T-cells 5 years after achieving remission, spontaneously became pregnant and delivered a healthy male infant. Our case provides an example of a healthy pregnancy despite the persistence of CAR T-cells and the resultant healthy newborn without evidence of immunologic or other health effects from the CAR T-cells.